Comparison of Changes in Serum 25(OH)D Concentrations Following Vitamin D Supplementation With Chewable Tablets Versus Pills

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02158598

Enrollment

Registered

2014-06-09

Start date

2014-06-30

Completion date

2018-05-09

Last updated

2018-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D Deficiency

Brief summary

This is a 6-month cross-over trial of vitamin D supplementation in 38 healthy men and women aged 18 years and older. The primary aim is to compare the change in serum 25(OH)D concentration following vitamin D supplementation with chewable tablets versus pills. Secondary aims are to evaluate satisfaction and adherence to the vitamin D chewable tablet supplement. Questionnaires on physical activity, sunlight exposure and dairy product consumption will be administered to adjust for confounding factors. A questionnaire will be administered to assess satisfaction and pill count to evaluate adherence to treatment. This research intends to test the hypothesis that the vitamin D chewable tablet supplement is as effective as a traditional vitamin D pill supplement to increase serum 25(OH)D concentrations.

Interventions

DRUGVitamin D chewable tablet supplementation

DRUGVitamin D pill supplementation

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Caucasian men and women; * Aged 18 years and older; * Having a serum 25(OH)D concentration of 75 nmol/L or less.

Exclusion criteria

* Regular consumption of a supplement containing \> 400 IU/d of vitamin D over the last 2 months; * Intestinal malabsorption; * Cirrhosis; * Renal insufficiency (creatinine clearance \<60 ml/min); * Hypercalcemia; * Pregnancy; * Breastfeeding; * Inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Change in Serum 25(OH)D concentration	0 and 2 months, 4 and 6 months

Secondary

Measure	Time frame	Description
Satisfaction with the vitamin D chewable tablets and pills.	0 and 2 months, 4 and 6 months	Satisfaction will be assessed using a questionnaire administered by the research team.
Adherence to the vitamin D chewable tablets and pills.	0 and 2 months, 4 and 6 months	This issue will be assessed by pill count.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026